Diagnostic, Pathologic, and Therapeutic Considerations for Primary CNS Lymphoma

Area of Science:

• Neuro-oncology
• Hematology
• Rare Cancers

Background:

• Primary CNS lymphoma (PCNSL) is a rare malignancy of the central nervous system, accounting for 3% of all brain tumors.
• Diagnosis and treatment are complicated by the risks of brain biopsy and the challenge of delivering therapeutics across the blood-brain barrier.
• While most patients are immunocompetent, HIV and immunosuppressive therapies are risk factors.

Purpose of the Study:

• To review the clinical, pathological, and therapeutic aspects of PCNSL.
• To highlight challenging clinical scenarios in managing PCNSL.
• To provide an overview for treating oncologists.

Main Methods:

• Literature review of clinical, pathological, and therapeutic data on PCNSL.
• Analysis of current treatment strategies and outcomes.
• Identification of challenging clinical situations.

Main Results:

• Improvements in frontline therapy and consolidation, including stem-cell transplantation, have enhanced survival rates.
• Despite advances, patients with relapsed or refractory PCNSL have poor prognoses.
• Effective treatment requires overcoming the blood-brain barrier and managing diagnostic complexities.

Conclusions:

• PCNSL management requires a multidisciplinary approach, considering diagnostic challenges and therapeutic limitations.
• Ongoing research is crucial for improving outcomes in relapsed or refractory PCNSL.
• Understanding PCNSL's unique aspects is vital for oncologists managing these rare tumors.